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Wound dressing is an important segment of the medical and pharmaceutical market worldwide. In the 
past, traditional dressings were used to simply manage wounds. Nowadays, wound dressings aim 
faster skin regeneration, oxygen exchange and lower microbial colonization.  
Acute wound therapies target specific phases of wound-healing, hemostasis, inflammation, 
proliferation and maturation, but do not consider possible disrupts on the usual conduct of each phase 
[1]. Due to a number of potential stimuli, ischemia, bioburden, necrotic tissue, trauma, etc., wounds 
can stall in one phase of healing, typically inflammation, contributing to wound chronicity [2]. 
Chronic wounds are often characterized by a defective matrix and cell debris impair healing, high 
bacteria counts, prolonged inflammation and moisture imbalance. Conventional therapies identify and 
remove these barriers to wound-healing by applying individualized treatments to each barrier [3].  
In the last years, synthetic biodegradable polymeric matrixes, e.g. poly(lactic acid) (PLA), 
poly(lactic-co-glycolic acid) (PLGA), poly(ɛ-caprolactone) (PCL) and polyurethane (PU), with 
versatile physical and mechanical properties, have demonstrated wound-healing abilities and enhanced 
re-epthelialization. The same capacities have been recognized in naturally occurring polymers, like 
cellulose and collagen [4]. In fact, collagen type I (Col I) has been highlighted as uniquely suited for 
wound dressing therapies because of its involvement in all phases of wound-healing. Platelets 
aggregate around exposed collagen and secrete factors that stimulate the intrinsic clotting cascade 
responsible for a stable hemostatic "plug". In addition, collagen dressings have the ability to absorb 
wound exudates to maintain a moist environment [5].  
Recently, the unique diverse function and architecture of antimicrobial peptides (AMPs) has 
attracted considerable attention as a tool in the design of molecular templates for new anti-infective 
drugs. AMPs are gene-encoded short amphipathic molecules with broad-spectrum antimicrobial 
activity. Some AMPs of mammal and amphibian origins have been identified as promoters of wound-
healing activities. LL37 (37 a.a.), the only cathelicidin-derived AMP found in humans, plays a central 
role in the innate immune response and inflammation [6]. Esculentin-1a(1-21)NH2 (20 a.a.) derived 
from the frog skin AMP esculentin-1a [7], and Tiger 17 (11 a.a.) synthesized from tigerinin AMPs [8] 
are known to act on different phases of wound-healing. Pexiganan (22 a.a.) synthesized from 
magaining is known to reduce microbial burden without enhancing bacterial resistance [9].  
In the present work, we proposed to engineer polymeric wound dressings by electrospinning for 
acute to chronic wound care that actively stimulate all phases of healing and prevent bacterial 
colonization. Synthetic and natural polymers (cellulose, PLA, PLGA, PCL and PU) are being 
electrospun in the form of mats and combined with Col I and AMPs, with immunoregulatory abilities, 
in one single therapy that will act on all barriers to wound healing: deficient cell matrix and debris 
impair healing, prolonged inflammation, high bacteria counts and moisture imbalance. Our strategy is 
target-directed by tuning the activity of each element composing the dressing.  
At the moment, we are in the first stage of our research, in the production of flexible and resistant 
single and multi-polymer dressings cross-linked with Col I by electrospinning. Different ranges of 
processing and solution conditions were tested: applied voltage (15-30 kV), flow rate (1-4 
mL/h), distance to collector (10-15 cm), environment temperature (13-25ºC), polymer 
concentration, viscosity, solvent volatility, surface tension and conductivity. Regardless the 
polymer used, the conditions were defined to obtain high, interconnected porosity and large 
surface area to allow both oxygen exchanges and exudates absorbency. Once we attained the 
proper dressings, the second stage, which consists in the covalent immobilization of the 
AMPs and posterior in vitro and in vivo testing, will start. This is a multidisciplinary project that 
is progressing very quickly. We are confident that multiple and viable solutions for wound care, with 
great potential to the biomedical field, will result from this strategy.  
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